Peptide reference
CJC-1295
DAC:GRF ·CJC-1295 with DAC ·CJC-1295 no-DAC (modified GRF 1-29) ·ConjuChem CJC-1295
What cited sources report about CJC-1295
CJC-1295 is a synthetic 30-amino-acid tetrasubstituted analog of growth hormone-releasing hormone (GRF 1-29), originally developed by ConjuChem. Two forms circulate in research and direct-to-consumer markets: a “no-DAC” form (sometimes called modified GRF 1-29) and a “DAC” form bearing a maleimidopropionic acid linker that binds covalently to serum albumin and substantially extends half-life. CJC-1295 has no FDA-approved indication and no marketing authorization in any major jurisdiction. The summaries below report what individual cited sources state; this page does not assert claims beyond what those sources report.
Mendias and Awan (2026) — Sports Medicine
A 2026 narrative review from the Performance Medicine Institute in Phoenix surveyed pharmacology, safety, and regulatory status of approved and unapproved peptide therapies marketed in sports medicine, with CJC-1295 categorized among the unapproved growth hormone secretagogues. The authors observed that animal-model data are more abundant than human data for these compounds, and noted that the gray-market supply chain operates largely outside regulatory oversight.
Many unapproved peptides demonstrate favorable tissue repair and metabolic outcomes in animal models, but rigorous human safety data are scarce, and there is potential for serious harm to patients.
Coutinho et al. (2026) — Journal of Sports Medicine and Physical Fitness
A critical review from the Faculty of Medical Sciences of Minas Gerais grouped CJC-1295 with sermorelin as GHRH analogues promoted in recreational and professional bodybuilding. The authors observed that emerging data highlight cardiovascular strain, insulin resistance, dyslipidemia, and psychiatric instability among potential risks of supraphysiological peptide use, and that contamination and mislabeling are common in the unregulated supply chain.
Until longitudinal data clarify their safety and prevalence, peptide use in both competitive and recreational settings should be considered high-risk and ethically problematic.
PubChem CID 56841945 — National Center for Biotechnology Information
The PubChem record catalogues CJC-1295 as a 30-residue tetrasubstituted analog of GRF 1-29 with substitutions at positions 2, 8, 15, and 27 designed to resist enzymatic degradation. The aggregate record covers both the unconjugated “no-DAC” form and the DAC variant that carries a maleimidopropionic-acid linker enabling covalent attachment to serum albumin in vivo.
DrugBank DB12865
The DrugBank entry lists CJC-1295 as an investigational peptide with status “experimental,” describing the GHRH-receptor-agonist mechanism and reporting no marketing authorization. The record cross-references early-phase ConjuChem development data and lists synonyms covering both formulations.
Coverage notes
Independent peer-reviewed human-trial data on CJC-1295 are limited to early-phase ConjuChem-sponsored studies from the late 2000s; the 2026 reviews by Mendias et al. and Coutinho et al. are the most recent secondary sources to discuss the compound in a regulatory context. No FDA-approved indication exists. CJC-1295 is named in multiple FDA warning letters issued to compounding pharmacies and supplement vendors; the FDA does not currently list CJC-1295 on its approved bulk drug substances list for compounding.